LifeMD Reports Third Quarter 2025 Results

Stock Information for Galectin Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Galectin Therapeutics Inc.

LifeMD Recognized by the 2025 Deloitte Technology Fast 500(TM) and by TIME's America's Growth Leaders of 2026
LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
LifeMD to Participate in the BTIG Digital Health Forum
LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
Portnoy Law Firm Announces Class Action on Behalf of LifeMD, Inc. Investors
LFMD FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Investors of LifeMD Upcoming Lead Plaintiff Deadline on Monday, October 27, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.